SCHEMBL8542007

SCHEMBL8542007

COC(=O)c1ccccc1-c1ccc(Br)cc1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 5/20 0.61
ALDH1A1 P00352 5/20 0.49
MAPT P10636 3/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
SLC6A4 P31645 3/20 0.49
SLC6A2 P23975 1/20 0.49
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
HSD17B3 P37058 1/20 0.46
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
NR4A2 P43354 1/20 0.44
ROCK2 O75116 1/20 0.44
CSF1R P07333 1/20 0.44
KDR P35968 1/20 0.44
FLT3 P36888 1/20 0.44
GSK3A P49840 1/20 0.44
GSK3B P49841 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7656620 0.85 SLC6A3 (0.61) SLC6A3ALDH1A1SLC6A4SLC6A2GAA
SCHEMBL9854193 0.84 SLC6A3 (0.43) SLC6A3ALDH1A1MAPTRAB9ANPC1
SCHEMBL12928420 0.84 SLC6A3 (0.57) SLC6A3ALDH1A1MAPTSLC6A4SLC6A2
SCHEMBL9549 0.82 SLC6A3 (0.57) SLC6A3ALDH1A1MAPTSLC6A4SLC6A2
SCHEMBL38659300 0.80 SLC6A3 (0.49) SLC6A3ALDH1A1MAPTSLC6A4SLC6A2
SCHEMBL28250780 0.80 SLC6A3 (0.49) SLC6A3ALDH1A1MAPTSLC6A4SLC6A2
SCHEMBL2267132 0.80 SLC6A3 (0.51) SLC6A3ALDH1A1MAPTSLC6A4SLC6A2
SCHEMBL2482051 0.80 NR4A2 (0.54) SLC6A3ALDH1A1MAPTGAAHTT
SCHEMBL69464 0.80 SLC6A3 (0.67) SLC6A3ALDH1A1MAPTSLC6A4SLC6A2
Bicarbonate SCHEMBL27492792 0.79 SLC6A3 (0.54) SLC6A3ALDH1A1MAPTSLC6A4SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0527851-B1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS SEARLE & CO (US) 1998-12-23 EP claimed
CN-109721628-B Fluorenyl thienopyrimidine luminescent materials 北京夏禾科技有限公司 2023-02-03 CN disclosed
CN-109721628-A FLUORENYL THIENOPYRIMIDINE LUMINESCENT MATERIALS 北京夏禾科技有限公司 2019-05-07 CN disclosed
US-20190127406-A1 FLUORENYL THIENOPYRIMIDINE LUMINESCENT MATERIALS Beijing Summer Sprout Technology Co., Ltd. (CN) 2019-05-02 US disclosed
US-20190127406-A1 FLUORENYL THIENOPYRIMIDINE LUMINESCENT MATERIALS Beijing Summer Sprout Technology Co., Ltd. (CN) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127406-A1 FLUORENYL THIENOPYRIMIDINE LUMINESCENT MATERIALS DPYD, TYMP, UMPS SLC6A3 1461/4885ALDH1A1 264/4885MAPT 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.